Montelukast Sodium represents an important class of medications used in respiratory medicine, particularly for managing asthma and allergic conditions. This leukotriene receptor antagonist has become a mainstay treatment option for various respiratory conditions since its approval in 1998. The following comprehensive review examines this medication’s properties, mechanisms, clinical applications, and safety profile.
Introduction
Montelukast Sodium is an orally administered leukotriene receptor antagonist widely prescribed for preventing and managing asthma symptoms, exercise-induced bronchoconstriction, and allergic rhinitis. Unlike rescue medications that provide immediate relief during asthma attacks, Montelukast functions as a controller medication designed for regular daily use to prevent symptoms and reduce inflammation in the airways.
Since receiving FDA approval in 1998 under the brand name Singulair, this medication has become available in various formulations including film-coated tablets, chewable tablets, and oral granules to accommodate different age groups and administration preferences.
Chemical Structure and Properties
Montelukast Sodium is chemically identified as 1-[[[(1R)-1-[3-(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]-methyl]-cyclopropaneacetic acid, monosodium salt. Its empirical formula is C35H35ClNO3S – Na with a molecular weight of 608.2 grams per mole. The compound features a quinoline ring system with a chlorine atom at the 7-position, connected by an ethenyl group to a complex structure containing a cyclopropaneacetic acid moiety.
The substance appears as a powder and demonstrates good solubility in various solvents including DMSO (50 mg/ml), water (30 mg/ml), and ethanol (60 mg/ml). This solubility profile contributes to its excellent bioavailability when administered orally. The chemical structure confers selective binding affinity to cysteinyl leukotriene receptors, which is central to its therapeutic mechanism of action.
Montelukast-Based Medicines
Several pharmaceutical manufacturers produce Montelukast-containing medications across global markets. The following represents eight prominent brand names:
- Singulair – Original brand developed by Merck, available in multiple formulations
- Montair – Marketed by Cipla Ltd., available as film-coated tablets, chewable tablets, and oral granules
- Monti – Produced by Abbott Healthcare Pvt. Ltd. in various dosages
- Montelast – Manufactured by Cadila Pharmaceuticals Ltd. in multiple formulations
- Jotair – Produced by D.R. Johns Labs in 5 mg and 10 mg formulations
- Maast – Marketed by Alchemist Life Science Ltd.
- Molly – Available through Allenge India Pharmaceuticals Pvt. Ltd.
- Lasma – Manufactured by Apex
These medications are generally available in three standard dosage strengths: 4 mg (primarily for pediatric use), 5 mg, and 10 mg (standard adult dosage).
Mechanism of Action
Montelukast functions through selective antagonism of cysteinyl leukotriene receptor type-1 (CysLT1). Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are inflammatory mediators released from various cells including mast cells, eosinophils, and macrophages during the inflammatory process. These leukotrienes are products of arachidonic acid metabolism and play significant roles in the pathophysiology of asthma and allergic conditions.
When leukotrienes bind to their receptors on airway cells such as macrophages and smooth muscle cells, they trigger various physiologic effects including airway edema, smooth muscle contraction, and altered cellular activity. By competitively binding to leukotriene receptors with high affinity, Montelukast blocks these inflammatory mediators from exerting their effects without demonstrating any agonist activity itself.
In controlled studies, Montelukast has been shown to significantly reduce beta2-agonist use (p<0.001), asthma symptoms (p=0.001), and blood eosinophils (p=0.009), while significantly increasing morning peak expiratory flow (p=0.001). These parameters demonstrate that Montelukast decreases airway eosinophilic inflammation and improves clinical respiratory function. The medication can inhibit bronchoconstriction with doses as low as 5 mg and can inhibit both early and late-phase bronchoconstriction caused by antigen challenge in asthmatic patients.
Pharmacokinetics
The pharmacokinetic profile of Montelukast has been well-characterized through multiple studies:
Absorption: Montelukast is rapidly absorbed following oral administration. After a 10 mg film-coated tablet is administered to fasted adults, the mean peak plasma concentration (Cmax) is achieved in 3 to 4 hours (Tmax). The oral bioavailability averages 64%. Importantly, standard meals do not significantly influence the oral bioavailability or maximum concentration when taken in the morning.
Distribution: The drug demonstrates extensive protein binding, with approximately 99% bound to plasma proteins. The steady-state volume of distribution is reported to range between 8 to 11 liters.
Metabolism: Montelukast undergoes extensive hepatic metabolism. At clinically relevant concentrations, cytochrome P450 2C8 appears to play the major role in its metabolism, with CYP3A4 and 2C9 also contributing to the biotransformation process. In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8. At therapeutic doses, plasma concentrations of montelukast metabolites are undetectable at steady state in both adults and pediatric patients.
Elimination: Montelukast and its metabolites are excreted almost exclusively via the bile. The pharmacokinetics of montelukast is linear for doses up to 50 mg.
Therapeutic Uses
| Indication | Age Group | Dosage | Notes |
|---|---|---|---|
| Chronic Asthma Management | Adults and children ≥2 years | 10 mg daily (adults), age-adjusted for children | Used as controller medication, not for acute attacks |
| Exercise-Induced Bronchoconstriction | ≥6 years | Typically 10 mg taken at least 2 hours before exercise | Not to be used as rescue medication during attacks |
| Seasonal Allergic Rhinitis | ≥2 years | 10 mg daily (adults), age-adjusted for children | Recommended when other treatments have not worked |
| Perennial Allergic Rhinitis | ≥6 months | 10 mg daily (adults), age-adjusted for children | Used for year-round allergy symptoms |
| Chronic Urticaria | Adults | 10 mg daily | Used for hives lasting >6 weeks (off-label in some regions) |
Most international asthma guidelines advise that children ≤5 years old with asthma be treated with daily low-moderate dose inhaled corticosteroids (ICS) as the preferred controller therapy, with montelukast indicated as an alternative treatment option.
Side Effects
Montelukast may cause various adverse effects ranging from common and mild to serious and potentially life-threatening. Patients should be monitored carefully for these effects, particularly neuropsychiatric symptoms.
Common Side Effects:
- Headache
- Gastrointestinal disturbances (heartburn, stomach pain, diarrhea)
- Fatigue or tiredness
- Upper respiratory tract infections
- Fever (particularly in children)
Serious Side Effects:
- Neuropsychiatric effects: agitation, depression, anxiety, sleep disturbances (including nightmares), hallucinations, suicidal thoughts or behaviors
- Allergic reactions: difficulty breathing or swallowing, swelling of face, throat, tongue, or lips, rash, hives, itching
- Eosinophilic conditions: flu-like symptoms, rash, pins and needles sensation in arms or legs
- Systemic vasculitis: pain and swelling of sinuses
- Hepatic effects: increased liver enzymes, hepatitis
- Severe skin reactions: blistering, peeling, or shedding skin
The FDA has emphasized the risk of neuropsychiatric events with Montelukast, which may occur during treatment or after discontinuation. These safety concerns prompted additional warnings in recent years.
Drug Interactions
Although Montelukast generally has a favorable drug interaction profile compared to many other medications, several important interactions have been documented:
Montelukast is metabolized primarily through CYP2C8, with contributions from CYP3A4 and 2C9 enzymes. Clinical studies investigating the effect of known inhibitors of these cytochromes (such as ketoconazole, erythromycin, or fluconazole) on Montelukast pharmacokinetics have not been extensively conducted. However, caution is advised when these inhibitors are co-administered.
Importantly, in vitro studies have identified Montelukast as a potent inhibitor of cytochrome P450 2C8, which may affect the metabolism of other drugs primarily metabolized by this enzyme. This interaction potential should be considered when prescribing Montelukast alongside other medications, particularly those with a narrow therapeutic index.
At therapeutic plasma concentrations, Montelukast does not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6, suggesting minimal potential for interactions with drugs metabolized through these pathways.
Safety Considerations
Several important safety considerations should guide the use of Montelukast:
Neuropsychiatric Effects: The FDA has issued specific warnings about serious mental health side effects associated with Montelukast. Patients should be monitored for behavioral changes, mood disturbances, suicidal thoughts or behaviors, and other neuropsychiatric symptoms. These effects may occur during treatment or after discontinuation.
Not for Acute Asthma Attacks: Montelukast is not intended for use as rescue medication during acute bronchospasm or asthma attacks. Patients should be clearly instructed about the role of this medication in their treatment plan.
Phenylketonuria Concerns: The chewable tablet formulations may contain phenylalanine, which could be harmful to patients with phenylketonuria (PKU).
Pregnancy and Breastfeeding: Limited data exist regarding safety during pregnancy and lactation. The benefits versus risks should be carefully evaluated.
Allergic Cross-Reactivity: Patients with known hypersensitivity to aspirin or other NSAIDs should use Montelukast with caution due to potential cross-reactivity.
Eosinophilic Conditions: Cases of systemic eosinophilia, sometimes with clinical features of vasculitis, have been reported in patients taking Montelukast. Healthcare providers should remain vigilant for these possible complications.
Regulatory Status
Montelukast was first approved for clinical use by the US FDA in 1998 under Merck’s brand name Singulair. It is currently available by prescription only in most countries worldwide. The medication is available in multiple formulations including film-coated tablets (typically 10 mg for adults), chewable tablets (4 mg and 5 mg), and oral granules (4 mg) for pediatric patients.
In recent years, regulatory agencies have strengthened warnings about neuropsychiatric effects associated with Montelukast. In 2020, the FDA required a Boxed Warning, the agency’s most prominent warning, about serious mental health side effects for Montelukast. The FDA now recommends that Montelukast should only be used for allergic rhinitis in patients who have inadequate response or cannot tolerate other allergy medications.
For asthma management, current treatment guidelines generally position Montelukast as an alternative controller medication rather than first-line therapy, particularly for children under 5 years of age.
Conclusion
Montelukast Sodium represents an important therapeutic option in the management of asthma and allergic conditions through its targeted inhibition of leukotriene receptors. Its convenient oral administration, once-daily dosing, and efficacy in preventing asthma symptoms and exercise-induced bronchoconstriction have made it a valuable medication for many patients. However, heightened awareness of potential neuropsychiatric effects has led to more cautious prescribing practices, particularly for patients with allergic rhinitis where alternative treatments may be considered first.
Healthcare providers must carefully balance the established benefits of Montelukast with its potential risks, especially neuropsychiatric effects, when determining its place in individual treatment regimens. Ongoing monitoring and patient education remain essential components of safe and effective Montelukast therapy. As with all medications, the therapeutic approach should be individualized based on patient-specific factors, treatment goals, and risk-benefit assessment.
